Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 3229 to 3239 of 3239 entries
Sorted by: Best Match Show Resources per page
Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke.

Science advances

Lemmerman LR, Balch MHH, Moore JT, Alzate-Correa D, Rincon-Benavides MA, Salazar-Puerta A, Gnyawali S, Harris HN, Lawrence W, Ortega-Pineda L, Wilch L, Risser IB, Maxwell AJ, Duarte-Sanmiguel S, Dodd D, Guio-Vega GP, McTigue DM, Arnold WD, Nimjee SM, Sen CK, Khanna S, Rink C, Higuita-Castro N, Gallego-Perez D.
PMID: 33741587
Sci Adv. 2021 Mar 19;7(12). doi: 10.1126/sciadv.abd4735. Print 2021 Mar.

Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to substantial functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here,...

Cite
Lemmerman LR, Balch MHH, Moore JT, et al. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Sci Adv. 2021;7(12)doi: 10.1126/sciadv.abd4735.
Lemmerman, L. R., Balch, M. H. H., Moore, J. T., Alzate-Correa, D., Rincon-Benavides, M. A., Salazar-Puerta, A., Gnyawali, S., Harris, H. N., Lawrence, W., Ortega-Pineda, L., Wilch, L., Risser, I. B., Maxwell, A. J., Duarte-Sanmiguel, S., Dodd, D., Guio-Vega, G. P., McTigue, D. M., Arnold, W. D., Nimjee, S. M., Sen, C. K., Khanna, S., Rink, C., Higuita-Castro, N., & Gallego-Perez, D. (2021). Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Science advances, 7(12), . https://doi.org/10.1126/sciadv.abd4735
Lemmerman, Luke R, et al. "Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke." Science advances vol. 7,12 (2021). doi: https://doi.org/10.1126/sciadv.abd4735
Lemmerman LR, Balch MHH, Moore JT, Alzate-Correa D, Rincon-Benavides MA, Salazar-Puerta A, Gnyawali S, Harris HN, Lawrence W, Ortega-Pineda L, Wilch L, Risser IB, Maxwell AJ, Duarte-Sanmiguel S, Dodd D, Guio-Vega GP, McTigue DM, Arnold WD, Nimjee SM, Sen CK, Khanna S, Rink C, Higuita-Castro N, Gallego-Perez D. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Sci Adv. 2021 Mar 19;7(12). doi: 10.1126/sciadv.abd4735. Print 2021 Mar. PMID: 33741587; PMCID: PMC7978431.
Copy Download .nbib Format: NLM
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)

Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
PMID: 34378456
Mult Scler. 2021 Aug 11;13524585211032803. doi: 10.1177/13524585211032803. Epub 2021 Aug 11.

BACKGROUND: Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS).OBJECTIVE: Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).METHODS: CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized 1:1:1...

Cite
Comi G, Dadon Y, Sasson N, et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler. 2021;13524585211032803doi: 10.1177/13524585211032803.
Comi, G., Dadon, Y., Sasson, N., Steinerman, J. R., Knappertz, V., Vollmer, T. L., Boyko, A., Vermersch, P., Ziemssen, T., Montalban, X., Lublin, F. D., Rocca, M. A., Volkinshtein, R., Rubinchick, S., Halevy, N., & Filippi, M. (2021). CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 13524585211032803. https://doi.org/10.1177/13524585211032803
Comi, Giancarlo, et al. "CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis." Multiple sclerosis (Houndmills, Basingstoke, England) vol. (2021): 13524585211032803. doi: https://doi.org/10.1177/13524585211032803
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler. 2021 Aug 11;13524585211032803. doi: 10.1177/13524585211032803. Epub 2021 Aug 11. PMID: 34378456.
Copy Download .nbib Format: NLM
Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial.

Schizophrenia research

Schandrin A, Picot MC, Marin G, André M, Gardes J, Léger A, O'Donoghue B, Raffard S, Abbar M, Capdevielle D.
PMID: 34991040
Schizophr Res. 2022 Jan 03;240:103-112. doi: 10.1016/j.schres.2021.12.016. Epub 2022 Jan 03.

BACKGROUND: Lack of insight is a barrier to treating psychosis. Preliminary studies have suggested that showing people videos of their psychotic behaviour may improve personal insight. This clinical trial aimed to assess the effect of video self-confrontation.METHODS: Inpatients between...

Cite
Schandrin A, Picot MC, Marin G, et al. Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial. Schizophr Res. 2022;240:103-112doi: 10.1016/j.schres.2021.12.016.
Schandrin, A., Picot, M. C., Marin, G., André, M., Gardes, J., Léger, A., O'Donoghue, B., Raffard, S., Abbar, M., & Capdevielle, D. (2022). Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial. Schizophrenia research, 240103-112. https://doi.org/10.1016/j.schres.2021.12.016
Schandrin, A, et al. "Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial." Schizophrenia research vol. 240 (2022): 103-112. doi: https://doi.org/10.1016/j.schres.2021.12.016
Schandrin A, Picot MC, Marin G, André M, Gardes J, Léger A, O'Donoghue B, Raffard S, Abbar M, Capdevielle D. Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial. Schizophr Res. 2022 Jan 03;240:103-112. doi: 10.1016/j.schres.2021.12.016. Epub 2022 Jan 03. PMID: 34991040.
Copy Download .nbib Format: NLM
Chronic Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta) with Cisterna Magna Ports: Update on Refinements.

Comparative medicine

Gilberto DB, Michener MS, Smith BE, Szczerba PJ, Holahan MA, Gray TL, Motzel SL.
PMID: 34903315
Comp Med. 2021 Dec 13; doi: 10.30802/AALAS-CM-21-000060. Epub 2021 Dec 13.

More than 20 y ago, we developed an animal model for chronic and continuous collection of cerebrospinal fluid (CSF) from conscious rhesus macaques. Since our previous publication in 2003, we have successfully implanted 168 rhesus macaquesusing this approach. Our...

Cite
Gilberto DB, Michener MS, Smith BE, et al. Chronic Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta) with Cisterna Magna Ports: Update on Refinements. Comp Med. 2021;doi: 10.30802/AALAS-CM-21-000060.
Gilberto, D. B., Michener, M. S., Smith, B. E., Szczerba, P. J., Holahan, M. A., Gray, T. L., & Motzel, S. L. (2021). Chronic Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta) with Cisterna Magna Ports: Update on Refinements. Comparative medicine, . https://doi.org/10.30802/AALAS-CM-21-000060
Gilberto, David B, et al. "Chronic Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta) with Cisterna Magna Ports: Update on Refinements." Comparative medicine vol. (2021). doi: https://doi.org/10.30802/AALAS-CM-21-000060
Gilberto DB, Michener MS, Smith BE, Szczerba PJ, Holahan MA, Gray TL, Motzel SL. Chronic Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta) with Cisterna Magna Ports: Update on Refinements. Comp Med. 2021 Dec 13; doi: 10.30802/AALAS-CM-21-000060. Epub 2021 Dec 13. PMID: 34903315.
Copy Download .nbib Format: NLM
Project Last Mile and the development of the Girl Champ brand in eSwatini: engaging the private sector to promote uptake of health services among adolescent girls and young women.

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

Brault MA, Christie S, Aquino S, Rendin A, Manchia A, Curry LA, Linnander EL.
PMID: 33685358
SAHARA J. 2021 Dec;18(1):52-63. doi: 10.1080/17290376.2021.1894224.

In eSwatini and across sub-Saharan Africa, adolescent girls and young women (AGYW) are at significantly higher risk of HIV infection and poorer sexual and reproductive health (SRH) than their male counterparts. AGYW demonstrate low demand for SRH services, further...

Cite
Brault MA, Christie S, Aquino S, et al. Project Last Mile and the development of the Girl Champ brand in eSwatini: engaging the private sector to promote uptake of health services among adolescent girls and young women. SAHARA J. 2021;18(1):52-63doi: 10.1080/17290376.2021.1894224.
Brault, M. A., Christie, S., Aquino, S., Rendin, A., Manchia, A., Curry, L. A., & Linnander, E. L. (2021). Project Last Mile and the development of the Girl Champ brand in eSwatini: engaging the private sector to promote uptake of health services among adolescent girls and young women. SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 18(1), 52-63. https://doi.org/10.1080/17290376.2021.1894224
Brault, Marie A, et al. "Project Last Mile and the development of the Girl Champ brand in eSwatini: engaging the private sector to promote uptake of health services among adolescent girls and young women." SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance vol. 18,1 (2021): 52-63. doi: https://doi.org/10.1080/17290376.2021.1894224
Brault MA, Christie S, Aquino S, Rendin A, Manchia A, Curry LA, Linnander EL. Project Last Mile and the development of the Girl Champ brand in eSwatini: engaging the private sector to promote uptake of health services among adolescent girls and young women. SAHARA J. 2021 Dec;18(1):52-63. doi: 10.1080/17290376.2021.1894224. PMID: 33685358; PMCID: PMC7946024.
Copy Download .nbib Format: NLM
Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose.

Frontiers in pharmacology

Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, Jochnowitz N, Kraus RL, Klein RM, Henze DA, Houghton AK, Burgey CS, Gibson C, Struyk A.
PMID: 35002718
Front Pharmacol. 2021 Dec 24;12:786078. doi: 10.3389/fphar.2021.786078. eCollection 2021.

MK-2075 is a small-molecule selective inhibitor of the NaV1.7 channel investigated for the treatment of postoperative pain. A translational strategy was developed for MK-2075 to quantitatively interrelate drug exposure, target modulation, and the desired pharmacological response in preclinical animal...

Cite
Ballard JE, Pall PS, Vardigan J, et al. Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Front Pharmacol. 2021;12:786078doi: 10.3389/fphar.2021.786078.
Ballard, J. E., Pall, P. S., Vardigan, J., Zhao, F., Holahan, M. A., Zhou, X., Jochnowitz, N., Kraus, R. L., Klein, R. M., Henze, D. A., Houghton, A. K., Burgey, C. S., Gibson, C., & Struyk, A. (2021). Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in pharmacology, 12786078. https://doi.org/10.3389/fphar.2021.786078
Ballard, Jeanine E, et al. "Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose." Frontiers in pharmacology vol. 12 (2021): 786078. doi: https://doi.org/10.3389/fphar.2021.786078
Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, Jochnowitz N, Kraus RL, Klein RM, Henze DA, Houghton AK, Burgey CS, Gibson C, Struyk A. Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Front Pharmacol. 2021 Dec 24;12:786078. doi: 10.3389/fphar.2021.786078. eCollection 2021. PMID: 35002718; PMCID: PMC8740778.
Copy Download .nbib Format: NLM
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.

Metabolism: clinical and experimental

Miele L, Zocco MA, Pizzolante F, De Matthaeis N, Ainora ME, Liguori A, Gasbarrini A, Grieco A, Rapaccini G.
PMID: 32916154
Metabolism. 2020 Nov;112:154355. doi: 10.1016/j.metabol.2020.154355. Epub 2020 Sep 09.

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and represent a common finding in highly prevalent metabolic disorders (i.e. type 2 diabetes, metabolic syndrome, obesity). Non-alcoholic steatohepatitis (NASH) requires liver biopsy for grading and...

Cite
Miele L, Zocco MA, Pizzolante F, et al. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism. 2020;112:154355doi: 10.1016/j.metabol.2020.154355.
Miele, L., Zocco, M. A., Pizzolante, F., De Matthaeis, N., Ainora, M. E., Liguori, A., Gasbarrini, A., Grieco, A., & Rapaccini, G. (2020). Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism: clinical and experimental, 112154355. https://doi.org/10.1016/j.metabol.2020.154355
Miele, Luca, et al. "Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease." Metabolism: clinical and experimental vol. 112 (2020): 154355. doi: https://doi.org/10.1016/j.metabol.2020.154355
Miele L, Zocco MA, Pizzolante F, De Matthaeis N, Ainora ME, Liguori A, Gasbarrini A, Grieco A, Rapaccini G. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism. 2020 Nov;112:154355. doi: 10.1016/j.metabol.2020.154355. Epub 2020 Sep 09. PMID: 32916154.
Copy Download .nbib Format: NLM
Calmodulin binds the N-terminus of the functional amyloid Orb2A inhibiting fibril formation.

PloS one

Soria MA, Cervantes SA, Siemer AB.
PMID: 35025866
PLoS One. 2022 Jan 13;17(1):e0259872. doi: 10.1371/journal.pone.0259872. eCollection 2022.

The cytoplasmic polyadenylation element-binding protein Orb2 is a key regulator of long-term memory (LTM) in Drosophila. The N-terminus of the Orb2 isoform A is required for LTM and forms cross-β fibrils on its own. However, this N-terminus is not...

Cite
Soria MA, Cervantes SA, Siemer AB. Calmodulin binds the N-terminus of the functional amyloid Orb2A inhibiting fibril formation. PLoS One. 2022;17(1):e0259872doi: 10.1371/journal.pone.0259872.
Soria, M. A., Cervantes, S. A., & Siemer, A. B. (2022). Calmodulin binds the N-terminus of the functional amyloid Orb2A inhibiting fibril formation. PloS one, 17(1), e0259872. https://doi.org/10.1371/journal.pone.0259872
Soria, Maria A, et al. "Calmodulin binds the N-terminus of the functional amyloid Orb2A inhibiting fibril formation." PloS one vol. 17,1 (2022): e0259872. doi: https://doi.org/10.1371/journal.pone.0259872
Soria MA, Cervantes SA, Siemer AB. Calmodulin binds the N-terminus of the functional amyloid Orb2A inhibiting fibril formation. PLoS One. 2022 Jan 13;17(1):e0259872. doi: 10.1371/journal.pone.0259872. eCollection 2022. PMID: 35025866; PMCID: PMC8758002.
Copy Download .nbib Format: NLM
Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury.

Scientific reports

Soranno DE, Baker P, Kirkbride-Romeo L, Wennersten SA, Ding K, Keith B, Cavasin MA, Altmann C, Bagchi RA, Haefner KR, Montford J, Gist KM, Vergnes L, Reue K, He Z, Elajaili H, Okamura K, Nozik E, McKinsey TA, Faubel S.
PMID: 35022484
Sci Rep. 2022 Jan 12;12(1):643. doi: 10.1038/s41598-021-04701-x.

Acute kidney injury (AKI) is common in patients, causes systemic sequelae, and predisposes patients to long-term cardiovascular disease. To date, studies of the effects of AKI on cardiovascular outcomes have only been performed in male mice. We recently demonstrated...

Cite
Soranno DE, Baker P, Kirkbride-Romeo L, et al. Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury. Sci Rep. 2022;12(1):643doi: 10.1038/s41598-021-04701-x.
Soranno, D. E., Baker, P., Kirkbride-Romeo, L., Wennersten, S. A., Ding, K., Keith, B., Cavasin, M. A., Altmann, C., Bagchi, R. A., Haefner, K. R., Montford, J., Gist, K. M., Vergnes, L., Reue, K., He, Z., Elajaili, H., Okamura, K., Nozik, E., McKinsey, T. A., & Faubel, S. (2022). Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury. Scientific reports, 12(1), 643. https://doi.org/10.1038/s41598-021-04701-x
Soranno, Danielle E, et al. "Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury." Scientific reports vol. 12,1 (2022): 643. doi: https://doi.org/10.1038/s41598-021-04701-x
Soranno DE, Baker P, Kirkbride-Romeo L, Wennersten SA, Ding K, Keith B, Cavasin MA, Altmann C, Bagchi RA, Haefner KR, Montford J, Gist KM, Vergnes L, Reue K, He Z, Elajaili H, Okamura K, Nozik E, McKinsey TA, Faubel S. Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemia-reperfusion acute kidney injury. Sci Rep. 2022 Jan 12;12(1):643. doi: 10.1038/s41598-021-04701-x. PMID: 35022484; PMCID: PMC8755805.
Copy Download .nbib Format: NLM
NKX2.1 run-on mutation associated to familial brain-lung-thyroid syndrome.

Clinical genetics

Cavaliere E, Gortan AJ, Passon N, Fabbro D, Marin D, Carecchio M, Baldan F, Credendino SC, Gallo R, Cogo P, Damante G, De Vita G.
PMID: 33778944
Clin Genet. 2021 Jul;100(1):114-116. doi: 10.1111/cge.13961. Epub 2021 Mar 29.

No abstract available.

Cite
Cavaliere E, Gortan AJ, Passon N, et al. NKX2.1 run-on mutation associated to familial brain-lung-thyroid syndrome. Clin Genet. 2021;100(1):114-116doi: 10.1111/cge.13961.
Cavaliere, E., Gortan, A. J., Passon, N., Fabbro, D., Marin, D., Carecchio, M., Baldan, F., Credendino, S. C., Gallo, R., Cogo, P., Damante, G., & De Vita, G. (2021). NKX2.1 run-on mutation associated to familial brain-lung-thyroid syndrome. Clinical genetics, 100(1), 114-116. https://doi.org/10.1111/cge.13961
Cavaliere, Elena, et al. "NKX2.1 run-on mutation associated to familial brain-lung-thyroid syndrome." Clinical genetics vol. 100,1 (2021): 114-116. doi: https://doi.org/10.1111/cge.13961
Cavaliere E, Gortan AJ, Passon N, Fabbro D, Marin D, Carecchio M, Baldan F, Credendino SC, Gallo R, Cogo P, Damante G, De Vita G. NKX2.1 run-on mutation associated to familial brain-lung-thyroid syndrome. Clin Genet. 2021 Jul;100(1):114-116. doi: 10.1111/cge.13961. Epub 2021 Mar 29. PMID: 33778944; PMCID: PMC8251915.
Copy Download .nbib Format: NLM
Innovative approach to research training: Research colloquium for junior investigators.

Balon Richard, Guerra Ernesto, Meador-Woodruff JamesH, Oquendo MariaA, Salloum IhsanM, Casiano DelaneE, Nemeroff CharlesB.
UIID-AD: 1455
2011;35:11-14. doi: 10.1176/appi.ap.35.1.11.

Training future clinical researchers is clearly a critical issue for psychiatry and medicine. How will a new generation of competent researchers be prepared to face these new challenges? Research training should be an essential part of all physician training....

Cite
Balon Richard, Guerra Ernesto, Meador-Woodruff JamesH, et al. Innovative approach to research training: Research colloquium for junior investigators. 2011;35:11-14doi: 10.1176/appi.ap.35.1.11.
Balon, R. i. c. h. a. r. d., Guerra, E. r. n. e. s. t. o., Meador-Woodruff, J. a. m. e. s. H., Oquendo, M. a. r. i. a. A., Salloum, I. h. s. a. n. M., Casiano, D. e. l. a. n. e. E., & Nemeroff, C. h. a. r. l. e. s. B. (2011). Innovative approach to research training: Research colloquium for junior investigators. 3511-14. https://doi.org/10.1176/appi.ap.35.1.11
Balon, Richard, et al. "Innovative approach to research training: Research colloquium for junior investigators." vol. 35 (2011): 11-14. doi: https://doi.org/10.1176/appi.ap.35.1.11
Balon Richard, Guerra Ernesto, Meador-Woodruff JamesH, Oquendo MariaA, Salloum IhsanM, Casiano DelaneE, Nemeroff CharlesB. Innovative approach to research training: Research colloquium for junior investigators. 2011;35:11-14. doi: 10.1176/appi.ap.35.1.11. UIID-AD: 1455.
Copy Download .nbib Format: NLM
Showing 3229 to 3239 of 3239 entries